Project Grant R01HL182417
Award Date 9/15/25
Completion Date 6/30/30
Dollars Obligated $571K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- This Project Grant award for $1,063,324 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on CD4+ T cell immunity in the respiratory tract, with a focus on understanding the mechanisms underlying host defense against extracellular pathogens, particularly in the area of Type 17 cytokines and tissue resident memory CD4+ T cells. The research will utilize murine and primate respiratory tract samples to assess the metabolic...
- This federal Project Grant award of $248,955 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Howard University to characterize the roles of bivalent chromatin domains in regulating CD4+ T cell differentiation and plasticity. The award will enable the principal investigator to expand their biological skills and apply a novel single-cell epigenetic profiling technique (iSCCHIC-seq) to study how bivalent domains regulate...
- The federal Project Grant award of $108,978.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanisms underlying the age-related decline in the regenerative capacity of alveolar type 2 (AT2) cells in the lung. The principal investigator and research team at the Harvard T.H. Chan School of Public Health will conduct studies to determine whether elevated interferon gamma (IFNG) levels and changes in resident...
- This Project Grant award, valued at $167,400.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), will support research by Brigham & Women's Hospital Inc. to investigate how the immune mediator CD70 regulates endothelial metabolism and function, with the goal of identifying novel therapeutic targets for atherosclerotic cardiovascular disease. The 5-year project will comprehensively examine the role of CD70 in impairing endothelial...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is for a targeted approach to treat immunotherapy-induced myocarditis (inflammation of the heart) using CXCR3 blockade. The total funding amount is $773,843, awarded on September 19, 2025, with an ultimate completion date of May 31, 2029. The key products and services to be delivered under this grant include: Validating the role of CXCR3-positive CD8+ T cells and...
- This $385,381 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of dynamic biological hydrogels to modulate cardiac remodeling following myocardial infarction. The primary goals are to: 1) Improve the mechanical stability and stiffness of cardiac extracellular matrix hydrogels compared to existing therapies, and 2) Leverage changes in extracellular matrix composition to promote a more regenerative...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $760,759 to the University of Illinois to examine the immunoregulatory role of a specific dendritic cell subset, CX3CR1+CDC2, in allergic lung inflammation. The project aims to characterize the anti-inflammatory functions of this cell population and its impact on regulatory T cell development and the resolution of allergic asthma symptoms. Through the use of novel...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $125,250 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 2-year research study on the role of the cytokine FAM3D in heart failure. The principal investigator, Dr. James Rhee, will lead a team of scientists to investigate how FAM3D regulates cardiac fibroblasts and the lymphatic system to limit inflammation and...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $773,479 to President and Fellows of Harvard College to develop a novel gene editing system for studying the effects of mitochondrial DNA (mtDNA) mutations on human cardiomyocyte function. The goal is to use this "MEDITORS" system to introduce, rescue, and regulate the heteroplasmy (mutation levels) of the common MELAS mtDNA mutation (m.3243A>G) in...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to support research on modulating the resolution of angiogenesis and normalizing the vasculature for therapeutic benefit in cardiovascular diseases. The $549,665 award, effective January 15, 2025 through November 30, 2028, will fund research conducted by the University of Maryland, Baltimore to investigate mechanisms that regulate the resolution of angiogenesis,...